

---

STATUTORY INSTRUMENTS

---

**2009 No. 389**

**MEDICINES  
FEES AND CHARGES  
CONSUMER PROTECTION**

The Medicines (Products for Human  
Use) (Fees) Regulations 2009 (revoked)<sup>F1</sup>

*Made - - - - 23rd February 2009*

*Laid before Parliament 5th March 2009*

*Coming into force 1st April 2009*

**THE MEDICINES (PRODUCTS FOR HUMAN  
USE) (FEES) REGULATIONS 2009 (REVOKED)**

PART 1

General

1. Citation and commencement
2. Interpretation

PART 2

Capital Fees for Pre-Application Meetings

3. Interpretation of Part 2
4. Fee for scientific advice: application for or variation to EC marketing authorization
5. Fee for scientific advice: classification of a medicinal product
6. Fee for advertising advice
7. Fee for pharmacovigilance advice
8. Fee for advice on labelling or leaflets
9. Fee for regulatory advice
10. Fee for advice for other purposes
11. Time for payment of fees under regulations 4 to 10

**Changes to legislation:** There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked). (See end of Document for details)

### PART 3

#### Capital Fees for Applications for Authorizations, Registrations, Licences, Certificates or Authorisations and for Associated Inspections

12. Fees for applications for authorizations, licences or certificates etc.
13. Fee for applications for copy certificates of good manufacturing practice
14. Fees for applications for certificates and copy certificates by exporters of medicinal products

### PART 4

#### Capital Fees for Assistance in Obtaining Marketing Authorizations in Other EEA States

15. Meaning of “set of applications”
16. Fees for applications for regulatory assistance under the mutual recognition procedure
17. Time for payment of fees under regulation 16

### PART 5

#### Capital Fees for Applications for Variations of Authorizations, Registrations, Licences and Certificates and for Associated Inspections

18. Fees for variations of authorizations, registrations, licences and authorisations
- 18A. Fees for a variation to the terms of a marketing authorization
19. Fees for amendments to clinical trial authorisations
20. Applications for multiple variations
- 20A. Applications for variations to the terms of a marketing authorization

### PART 6

#### Capital Fees for Assessment of Labels and Leaflets

21. Meaning of “set of proposed changes”
22. Fees for assessment of a set of proposed changes to labels and leaflets
23. Time for payment of fees under regulation 22

### PART 7

#### Capital Fees for Applications for Renewals of Certain Licences, Authorizations and Registrations and for Associated Inspections

24. Fees for renewals of certain manufacturer's licences
25. Fees for renewals in terms which are not identical to the existing authorization, licence or certificate

### PART 8

#### Capital Fees for Regulatory Assistance Given by the United Kingdom Acting as Reference Member State Relating to the Assessment of Applications for the Renewal of Specified Marketing Authorizations

26. Fees for regulatory assistance for certain marketing authorizations

## PART 9

### Capital Fees for Inspections

27. Fees for inspections
28. Payer of inspection fee (contract laboratories and API manufacturing sites)
29. Inspections in connection with multiple applications
30. Fees for inspections relating to good clinical practice in clinical trials
31. Amount of and time for payment of inspection fees in respect of an application for a wholesale dealer's licence
32. Adjustment and refund of inspection fees in respect of a wholesale dealer's licence

## PART 10

### Periodic Fees for Marketing Authorizations and Licences

33. Periodic fees
34. Periodic fees for clinical trial authorisations

## PART 11

### Capital Fees For Application For Membership of Good Clinical Practice Accreditation Scheme and for Certificate of Membership

35. Meaning of “good clinical practice accreditation” scheme
36. Fees for applications for membership and certificate

## PART 12

### Capital Fee for a Person Appointed Hearing

37. Fee for a person appointed hearing
38. Time for payment under regulation 37

## PART 13

### Administration

39. Payment of fees to Ministers
40. Time for payment of capital fees in connection with applications or inspections
41. Time for payment of capital fees – applications made by small companies
42. Payment of fees in respect of a traditional herbal registration
43. Time for payment of periodic fees
44. Penalty fees for late payment of periodic fees
45. Daily penalty fees for late payment of periodic fees
46. Refund or waiver of fees under regulation 44 or 45
47. Adjustment, waiver, reduction or refund of fees
48. Suspension of licences and authorisations
49. Civil proceedings to recover unpaid fees

## PART 14

50. Amendment of the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994

**Changes to legislation:** There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked). (See end of Document for details)

## PART 15

### Revocations and Savings

51. Revocations and savings  
Signature

---

## SCHEDULE 1 — CAPITAL FEES FOR APPLICATIONS FOR, AND VARIATIONS TO, MARKETING AUTHORIZATIONS, LICENCES AND CERTIFICATES

### PART 1 — General: interpretation and categories of applications and variations

1. Interpretation
2. General: categories of Applications and Variations
3. Administrative variation application
4. BROMI variations
5. Complex application
6. Complex registration application
7. Complex variation application
8. Decentralised procedure application
9. Extended Type II Complex Variation Application
10. Major application
11. Mutual recognition procedure incoming application
12. New excipient variation application
13. New indication variation application
14. Parallel Import Licence application
15. Reclassification variation application
16. Reduced registration application
17. Simple application
18. Standard application
19. Standard registration application
20. Standard variation application
21. Standard variation application for a homoeopathic medicinal product
22. Type IB and Type II Applications
23. Type II Complex Variation Application

### PART 2 — Capital Fees for Applications for Authorizations, Licences, Registrations and Certificates

24. Marketing authorizations
25. Fees where application includes reclassification
26. Fees where person holds clinical trial certificate
27. Joint development
28. Applications for multiple authorizations
29. Authorisation for a national homoeopathic product
30. Manufacturer's licences and authorisations
31. Wholesale dealer's licences
32. Clinical trial authorisations
33. Traditional herbal registrations

### PART 3 — Capital Fees for Assistance in Obtaining Marketing Authorizations in Other EEA States

34. Outgoing mutual recognition applications

### PART 4 — Capital Fees for Applications for Variations of Authorizations, Licences and Registrations

**Changes to legislation:** There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked). (See end of Document for details)

35. Marketing authorizations
- 35A Variations to the terms of marketing authorizations
36. Variation of marketing authorizations
37. Reclassification of marketing authorizations
38. Variation of marketing authorization: national homoeopathic products
39. Variation of parallel import licence
40. Manufacturer's authorisations and licences
41. Variation of manufacturer's authorisations and licences
42. Wholesale dealer's licences
43. Variation of wholesale dealer's licence
44. Clinical trial authorisations
45. Traditional herbal registrations
46. Identical variations
- 46A Reduced fees for Type IB and Type II Applications, Minor Variation (Type IB) Group Applications and a Major Variation (Type II) Group Applications
47. Complex Variation Applications
- 47A Reduced Fees for identical Type II Complex Applications, Extended Type II Complex Variation Applications, Major Variation (Type II) Complex Group Applications and Major Variation (Type II) Extended Complex Group Applications
48. Multiple reclassification variation applications
  - PART 5 — Capital Fees for Assessment of Labels and Leaflets
49. A set of changes
50. More than one set of charges proposed
  - PART 6 — Capital Fees for Regulatory Assistance Given by the United Kingdom Acting as Reference Member State Relating to the Assessment of Applications for the Renewal of Specified Marketing Authorizations
51. Regulatory assistance
52. Regulatory assistance – same manufacturer

#### SCHEDULE 2 — FEES FOR INSPECTIONS

1. General provisions relating to fees for inspections
2. Fees: general
3. Traditional herbal medicinal products
4. Sites concerned with starting materials for traditional herbal medicinal products
5. Wholesale dealer's licence: general
6. Wholesale dealer's licence: Traditional herbal medicinal products
7. Wholesale dealer's licences: inspection of short duration

#### SCHEDULE 3 — PERIODIC FEES FOR LICENCES

##### PART 1 — Interpretation

1. In this Schedule— “anthroposophic product” means a medicinal product prepared...

##### PART 2 — Calculation of Turnover

2. Calculation of turnover
3. Manufacturer's prices
4. Evidence of turnover

##### PART 3 — Periodic Fees for Marketing Authorizations and Licences

5. Marketing authorizations
6. Marketing authorization: where Part 2 of the Act applies

**Changes to legislation:** There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked). (See end of Document for details)

7. Marketing authorization: derivatives
8. Number of fee periods
9. Authorisation for two or more kinds of medicinal product
10. Reduced fees
11. Manufacturer's licences or manufacturing authorisations
12. Wholesale dealer's licences
13. Wholesale dealer's licences: evidence
14. Wholesale dealer licences: exempt imported products
15. Additional amount for manufacturer's licences and wholesale dealer's licences which relate to exempt imported products
16. Clinical trial authorisations
17. Traditional herbal registrations
  - PART 4 — Types of Marketing Authorization for which only One Periodic Fee is Payable
18. Specified parallel import licences

#### SCHEDULE 4 — TIME FOR PAYMENT OF CAPITAL FEES

1. Interpretation
2. Major application
3. Complex application
4. Multiple applications
5. Outgoing mutual recognition applications
6. Application for traditional herbal registration
7. Traditional herbal registration: complex variation
8. Application for manufacturer's licence, manufacturing authorisation or wholesale dealer's licence
9. Inspection fees in connection with applications

#### SCHEDULE 5 — WAIVER, REDUCTION OR REFUND OF CAPITAL FEES

1. Interruptions of manufacture, assembly, sale or supply
2. Reclassification
3. Variation of a traditional herbal registration
4. Withdrawal of application in relation to marketing authorization, traditional herbal registration or clinical trial authorisation
5. Withdrawal of application in relation to manufacturing authorisation, wholesale dealer's or manufacturer's licence
6. Refusal of application for grant of marketing authorization, traditional herbal registration or clinical trial authorisation
7. Parallel import licence
8. Surrender of marketing authorization at same time as a variation application
9. Clinical trial authorisation
10. Scientific advice: paediatric indications

#### SCHEDULE 6 — ADJUSTMENT, REDUCTION OR REFUND OF PERIODIC FEES

1. Refund on surrender or revocation of authorization, registration or licence
2. Adjustment and refund: licences relating to exempt imported products
3. Refunds: treated as having been paid on account

#### SCHEDULE 7 — INTERPRETATION

1. Interpretation
2. For the purposes of these Regulations, a clinical trial authorisation...
3. In these Regulations any reference to an application for the...

Document Generated: 2024-04-04

**Changes to legislation:** There are currently no known outstanding effects for the *The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked)*. (See end of Document for details)

Explanatory Note

**Changes to legislation:**

There are currently no known outstanding effects for the The Medicines (Products for Human Use) (Fees) Regulations 2009 (revoked).